SAHA (suberoylanilide hydroxamic acid) is a potent inhibitor of class I and class II histone deacetylases (HDACs)
This compound inhibits the activities of HDAC1 and HDAC3 (IC50 = 10 nM and 20 nM, respectively; Richon et al.) SAHA exhibits antiproliferative properties and can cause cell cycle arrest at G1 (Marks & Breslow)
Improves reprogramming efficiency from human and mouse somatic to induced pluripotent stem cells (Huangfu et al.)
Downregulates homologous recombination and leads to apoptosis in ovarian cancer cells when used in combination with olaparib (Konstantinopoulos et al.)
SAHA downregulates Nanog expression, which leads to proliferation inhibition in head and neck cancer stem cells (Kumar et al.)
